What Is OMass Therapeutics

OMass Therapeutics is a private biotechnology company, focused on structural mass spectrometry to discover novel medicines.

The company uses its suite of proprietary technologies based on high-resolution mass spectrometry to study intact protein assemblies. The technology enables detection of drug leads that not only bind to the target complex, but also exert a functional effect through modulation of complex formation, with both effects, binding and function, being measured by a change in mass. These methods are being applied to drug discovery for a variety of complex targets, including membrane receptors.

The

Science

We are developing novel medicines using our suite of proprietary technologies based on high-resolution mass spectrometry of intact protein assemblies.

Read More

Overview

About Us

We are a biotechnology company using structural mass spectrometry to discover novel medicines.

Read More

Latest News

OMass Therapeutics Expands its Senior Leadership Team
November 27, 2018

Dr Ali Jazayeri – Chief Scientific Officer Dr Giles Brown – VP, Medicinal Chemistry Dr Hsin Loke – VP, Head of…

Read More
OMass Therapeutics Announces £14 Million Series A Financing to Build a Pipeline of Proprietary Medicines
November 21, 2018

– Developing novel medicines using structural mass spectrometry – Oxford, 20 November 2018 – OMass Therapeutics (“OMass”), a biopharmaceutical company using…

Read More
OMass Therapeutics is Expanding its Team
November 20, 2018

Oxford, 20 November 2018 – OMass Therapeutics (“OMass”), a biotechnology company using structural mass spectrometry to discover novel medicines is expanding…

Read More
OMass Technologies Announces Publication Demonstrating the Impact of Lipid interactions on GPCR Signalling in Nature
July 11, 2018

Oxford, 11 July 2018 – OMass Technologies (“OMass”), a biotechnology company using structural mass spectrometry to drive drug discovery, today announced…

Read More